MANNKIND CORP — Director's Dealing 2023

May 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MANNKIND CORP (MNKD)
CIK: 0000899460
Period of Report: 2023-05-25

Reporting Person: Sabella Lauren M (EVP Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-25	Common Stock, $.01 Par Value	A	23250	$0.00	Acquired	247434	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-25	Performance Restricted Stock Unit	$	A	28000	Acquired		Common Stock, $.01 Par Value (28000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested.

F3: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.